brain cancer

[Molecular Neurobiology] The authors collate the most important discoveries relating to the neuroprotective effects of SOX1 in brain cancer and propose hypothesis worthy of SOX1’s role in the survival of senescent neuronal cells, its roles in fibroblast cell proliferation, and cell fate for neuroprotection, and the discharge of electrical impulses for homeostasis.

[Cell Death & Differentiation] The authors consider how knowledge of E3 ligase biology may be used for future therapeutic interventions in glioblastoma, including the use of blood-brain barrier permeable proteolysis targeting chimeras.

[Global Coalition for Adaptive Research] The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, announced the activation of Kazia's paxalisib and Kintara's VAL-083 in Glioblastoma Adaptive Global Innovative Learning Environment (AGILE).

[Humanigen, Inc.] Humanigen, Inc. announced completing enrollment in its Phase I bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme. Ifabotuzumab, or ifab, is the company’s proprietary anti-EphA3 monoclonal antibody.

[The Ivy Brain Tumor Center (GlobeNewswire, Inc.)] The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a Phase 0 clinical trial for patients with newly diagnosed and recurrent glioblastoma to evaluate pamiparib, an investigational small molecule PARP inhibitor from BeiGene.

[Flinders University (News-Medical)] Flinders University’s Dr. Cedric Bardy, Director of the Laboratory for Human Neurobiology at SAHMRI, says the need to understand how brain functions affect cancer cell development is urgent because the clinical outcomes of brain cancer remain extremely low.